Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M11.6Revenue $M11.5Net Margin (%)-209.3Altman Z-Score-20.5
Enterprise Value $M-7.3EPS $-1.1Operating Margin %-209.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score11.1Pre-tax Margin (%)-209.6Higher ROA y-yY
Price/Book1.110-y EBITDA Growth Rate %--Quick Ratio3.1Cash flow > EarningsN
Price/Sales0.95-y EBITDA Growth Rate %--Current Ratio3.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-74.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-232.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M27.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ONTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ONTXGeorge Soros 2014-09-30 Sold Out $4.325 - $5.64
($5.07)
$ 0.43-92%Sold Out0
ONTXGeorge Soros 2014-06-30 Buy $4.18 - $6.22
($5.24)
$ 0.43-92%New holding10,774
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONTX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ONTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Michael & Jane Hoffman 2013 De10% Owner 2014-02-21Buy143,480$8.47-94.92view
Hoffman Michael BDirector, 10% Owner 2014-02-21Buy143,480$8.47-94.92view
Kumar RameshPresident and CEO 2014-02-10Sell33,543$15.07-97.15view
Kumar RameshPresident and CEO 2014-02-03Sell60,000$15.05-97.14view
Hoffman Michael BDirector, 10% Owner 2014-01-27Buy57,295$11.92-96.39view
Michael & Jane Hoffman 2013 De10% Owner 2014-01-27Buy57,295$11.92-96.39view
Michael & Jane Hoffman 2013 De10% Owner 2013-11-22Buy5,000$14.39-97.01view
Hoffman Michael BDirector, 10% Owner 2013-11-22Buy5,000$14.39-97.01view
Reddy E PremkumarDirector 2013-11-18Buy5,000$12.1-96.45view
Hoffman Michael BDirector, 10% Owner 2013-11-18Buy5,000$11.87-96.38view

Quarterly/Annual Reports about ONTX:

    News about ONTX:

    Articles On GuruFocus.com
    Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

    More From Other Websites
    ETF’s with exposure to Onconova Therapeutics, Inc. : April 29, 2016 Apr 29 2016
    Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in... Apr 21 2016
    Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in... Apr 21 2016
    Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in... Apr 20 2016
    Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in... Apr 20 2016
    ETF’s with exposure to Onconova Therapeutics, Inc. : April 4, 2016 Apr 04 2016
    Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 01 2016
    ONCONOVA THERAPEUTICS, INC. Financials Mar 31 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 28 2016
    Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results Mar 28 2016
    Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results Mar 28 2016
    Onconova Starts Phase III INSPIRE Study on Rigosertib in EU Mar 23 2016
    Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk... Mar 21 2016
    Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk... Mar 21 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Mar 09 2016
    Onconova Announces Publication of Rigosertib Phase 3 ONTIME Data in Lancet Oncology Mar 09 2016
    Baxter spinoff cancels potential $565M partnership with Bucks County biotech firm Mar 04 2016
    Onconova Therapeutics, Inc. Receives Notice of Termination for Convenience from Baxalta Mar 03 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Feb 17 2016
    ONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 04 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)